Department of Health - Abu Dhabi and ŌURA Partner to Advance Preventive Health in Abu Dhabi
7.5.2026 18:57:00 CEST | Business Wire | Press Release
Department of Health—Abu Dhabi (DoH) and ŌURA, maker of the world’s leading smart ring, Oura Ring, today announced a joint research programme to study how continuous wearable data can advance preventive health. The collaboration marks the beginning of a long-term partnership to advance Abu Dhabi’s prevention-first, data-driven healthcare agenda, and will initially focus on women’s health and cardiometabolic risk.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507073495/en/
HE Mansoor Al Mansoori (Left) and Tom Hale (Right)
The collaboration builds on Abu Dhabi’s advanced public health infrastructure and longitudinal health data assets, integrating them with ŌURA’s real-time, continuous insights across key health indicators. Together, this creates a strong foundation for understanding health at a population level, enabling the identification of risk factors and supporting a shift from reactive care to more proactive, personalised intervention. The depth of Abu Dhabi’s longitudinal data further strengthens its potential as a platform for population health research, offering deeper insight into how conditions such as obesity, prediabetes, cardiovascular disease, and maternal health risks emerge and evolve.
Initially centred around women’s health, the partnership will explore key research pathways focused on preconception health and perinatal care, supporting the development of more targeted early interventions and improving health trajectories for women, families, and the wider population. The collaboration will also explore other key areas of health, including metabolic and cardiovascular conditions, with a clear ambition to scale successful insights and interventions beyond initial focus areas over time.
The partnership will be supported by robust data governance principles, including data minimization, transparent data processing and secure storage in line with applicable regulations and international best practices. All use of identifiable data will be strictly controlled, with access governed by jointly defined ethical and regulatory standards.
HE Mansoor Al Mansoori, Chairman of the Department of Health – Abu Dhabi, and Tom Hale, CEO of ŌURA met in LA, USA this week to formally launch the partnership and align on the next phase of advancing prevention-led, data-driven healthcare.
HE Al Mansoori commented: “The future of health will be defined by sensing and the ability to understand the body continuously, in real-time, and at population scale. Abu Dhabi has built an intelligent health system designed for this shift. Bringing real-world wearable data into the clinical setting, underpinned by strong data governance frameworks that ensure privacy and responsible use of health data.
“Advancing women's health and fertility is a key priority for Abu Dhabi, and together with ŌURA we are starting where continuous insights have the greatest power to detect risk earlier and create more personalised care across the life course - for mothers, babies, and families. This partnership brings together one of the world’s most advanced population health datasets with continuous wearable insights at scale, creating a unique opportunity to redefine how prevention is delivered in real-world settings.”
Tom Hale said: “Abu Dhabi is setting a powerful example for how nations can embed prevention and innovation into the future of healthcare. Partnering with the Department of Health – Abu Dhabi will allow us to build a meaningful preventative health model that is grounded in data, scientific rigor and privacy. It’s one of many upcoming initiatives we’re committed to across the region, and an important step in our long-term partnership with Abu Dhabi.
We’re starting with women’s health, because the health of women is the health of families, and the health of families is the health of the nation. But this partnership is just the beginning — our ambition is to develop a model here that can inform preventive care globally.”
The agreement marks a significant milestone in ŌURA’s continued expansion across the UAE and wider Gulf region, as the company deepens its presence through strategic partnerships, locally relevant research, and innovation aligned with the UAE’s emergence as a world leader in prevention-led healthcare and long-term wellbeing.
The next phase of the partnership will focus on pilot design, ethics approvals, and local evidence generation, creating a clear pathway toward broader integration within Abu Dhabi’s health system.
About the Department of Health –Abu Dhabi (DoH):
The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH’s unwavering commitment to predicting, preventing and personalising healthcare for every individual.
For further information on DOH, visit https://www.doh.gov.ae/ and follow on X, Instagram, Facebook, LinkedIn and YouTube.
About ŌURA:
ŌURA delivers personalized health data, insights, and daily guidance with Oura Ring, the leading smart ring that helps you live healthier, longer. Guided by a mission to shift healthcare from sick care to prevention, ŌURA supports millions of members worldwide across sleep, activity, stress, readiness, women’s health, and heart health. Scientifically validated against medical gold standards, the lightweight Oura Ring tracks 50+ health metrics continuously, empowering both individuals and thousands of research teams, healthcare providers, and organizations. With 1,000 ecosystem partners across wellness and medicine, ŌURA is advancing the future of preventative health.
Founded in Finland in 2013, ŌURA has E.U. headquarters in Oulu and U.S. headquarters in San Francisco. ŌURA was last valued at approximately $11B—making it the world’s most valuable standalone wearable company. Learn more at ouraring.com or connect with ŌURA on Instagram, LinkedIn, and TikTok.
Oura Ring is not a medical device and is not intended to diagnose, treat, cure, monitor, or prevent medical conditions or illnesses.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260507073495/en/
Contacts
ŌURA
For press enquiries contact:
oura@currentglobal.com
Department of Health – Abu Dhabi
For media inquiries, please contact:
Mariam Al Marzooqi,
msalmarzooqi@doh.gov.ae
+971 50 536 6660
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press Release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press Release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press Release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom